Alector Inc. (ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, has a clinical trial catalyst related to its investigational drug AL002 that is worth monitoring in the coming months.
AL002 is an engineered, humanized monoclonal immunoglobulin G1 (IgG1) antibody designed to target Triggering Receptor Expressed on Myeloid cells 2 (TREM2). Research suggests that reduction of TREM2 functionality may lead to Alzheimer's disease and other forms of dementia. AL002 is intended to counteract this decreased functionality by improving TREM2 signaling to enhance microglia activity. This compound is being developed in collaboration with AbbVie.
For comments and feedback contact: editorial@rttnews.com
June 19, 2026 16:46 ET Major central banks continued to dominate the economic news flow this week too, led by the Federal Reserve, as they announced their latest policy decisions. The Federal Reserve policy session was in focus as it was the first to be led by the new chief Kevin Warsh. In Europe, central banks of the U.K. and Switzerland announced their rate decisions. In Asia, the Bank of Japan drew attention for its policy moves, while data out of China threw some light on the state of the economy.